(PDEX) Pro-Dex - Ratings and Ratios
Surgical, Instruments, Drives, Components
PDEX EPS (Earnings per Share)
PDEX Revenue
Description: PDEX Pro-Dex August 18, 2025
Pro-Dex Inc (NASDAQ:PDEX) is a US-based company operating in the Health Care Equipment sub-industry. To evaluate its investment potential, well deconstruct its financials and key drivers.
The companys income tax expense is a crucial aspect of its financials. Analyzing this metric yearly can reveal trends in tax rates and potential impacts on profitability. A decreasing income tax expense could indicate improved tax efficiency or lower taxable income.
Key Performance Indicators (KPIs) to monitor for PDEX include Return on Equity (RoE), which stands at 29.08%, indicating strong profitability. The Price-to-Earnings (P/E) ratio is 13.92, suggesting a relatively reasonable valuation compared to its earnings. The forward P/E is 16.13, implying expected earnings growth.
Economic drivers for PDEX include demand for healthcare equipment, regulatory changes, and competition within the industry. As a healthcare equipment provider, PDEX is likely influenced by trends in healthcare spending, technological advancements, and the overall economic environment.
To assess PDEXs stock performance, we can examine its market capitalization, which is approximately $125.26 million. The stocks beta is 0.190, indicating relatively low volatility compared to the broader market. Other key metrics to consider include revenue growth, gross margin, and operating cash flow, which can provide insights into the companys financial health and operational efficiency.
By analyzing these factors and KPIs, we can better understand PDEXs investment potential and make more informed decisions. A thorough examination of its financials, industry trends, and competitive positioning is necessary to determine whether PDEX is an attractive investment opportunity.
PDEX Stock Overview
| Market Cap in USD | 101m |
| Sub-Industry | Health Care Equipment |
| IPO / Inception | 1995-08-18 |
PDEX Stock Ratings
| Growth Rating | 29.3% |
| Fundamental | 75.5% |
| Dividend Rating | - |
| Return 12m vs S&P 500 | -3.77% |
| Analyst Rating | 5.0 of 5 |
PDEX Dividends
Currently no dividends paidPDEX Growth Ratios
| Growth Correlation 3m | -84.3% |
| Growth Correlation 12m | -36.2% |
| Growth Correlation 5y | 22.2% |
| CAGR 5y | 24.53% |
| CAGR/Max DD 3y (Calmar Ratio) | 0.38 |
| CAGR/Mean DD 3y (Pain Ratio) | 1.41 |
| Sharpe Ratio 12m | -0.15 |
| Alpha | 17.31 |
| Beta | -0.107 |
| Volatility | 72.48% |
| Current Volume | 137k |
| Average Volume 20d | 48.6k |
| Stop Loss | 34.3 (-5.4%) |
| Signal | 0.38 |
Piotroski VR‑10 (Strict, 0-10) 6.5
| Net Income (8.98m TTM) > 0 and > 6% of Revenue (6% = 4.00m TTM) |
| FCFTA -0.05 (>2.0%) and ΔFCFTA -14.79pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 49.05% (prev 43.56%; Δ 5.49pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA -0.03 (>3.0%) and CFO -1.68m <= Net Income 8.98m (YES >=105%, WARN >=100%) |
| Net Debt (15.7m) to EBITDA (14.1m) ratio: 1.11 <= 3.0 (WARN <= 3.5) |
| Current Ratio 3.23 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (3.35m) change vs 12m ago -3.53% (target <= -2.0% for YES) |
| Gross Margin 29.30% (prev 27.41%; Δ 1.89pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 115.4% (prev 99.32%; Δ 16.09pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 15.55 (EBITDA TTM 14.1m / Interest Expense TTM 829.0k) >= 6 (WARN >= 3) |
Altman Z'' 8.48
| (A) 0.53 = (Total Current Assets 47.3m - Total Current Liabilities 14.6m) / Total Assets 61.2m |
| (B) 0.59 = Retained Earnings (Balance) 35.9m / Total Assets 61.2m |
| (C) 0.22 = EBIT TTM 12.9m / Avg Total Assets 57.7m |
| (D) 1.49 = Book Value of Equity 36.6m / Total Liabilities 24.6m |
| Total Rating: 8.48 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 75.51
| 1. Piotroski 6.50pt = 1.50 |
| 2. FCF Yield -2.66% = -1.33 |
| 3. FCF Margin -4.40% = -1.65 |
| 4. Debt/Equity 0.45 = 2.40 |
| 5. Debt/Ebitda 1.11 = 1.61 |
| 6. ROIC - WACC (= 14.49)% = 12.50 |
| 7. RoE 26.67% = 2.22 |
| 8. Rev. Trend 93.00% = 6.97 |
| 9. EPS Trend 25.57% = 1.28 |
What is the price of PDEX shares?
Over the past week, the price has changed by +27.61%, over one month by +7.06%, over three months by -27.59% and over the past year by +16.83%.
Is Pro-Dex a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of PDEX is around 31.40 USD . This means that PDEX is currently overvalued and has a potential downside of -13.36%.
Is PDEX a buy, sell or hold?
- Strong Buy: 1
- Buy: 0
- Hold: 0
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the PDEX price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 56 | 54.5% |
| Analysts Target Price | 56 | 54.5% |
| ValueRay Target Price | 33.9 | -6.5% |
PDEX Fundamental Data Overview October 31, 2025
P/E Trailing = 11.5019
P/E Forward = 19.1571
P/S = 1.5126
P/B = 2.9911
Beta = -0.107
Revenue TTM = 66.6m USD
EBIT TTM = 12.9m USD
EBITDA TTM = 14.1m USD
Long Term Debt = 9.25m USD (from longTermDebt, last quarter)
Short Term Debt = 6.65m USD (from shortTermDebt, last quarter)
Debt = 16.6m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 15.7m USD (from netDebt column, last quarter)
Enterprise Value = 110.1m USD (100.7m + Debt 16.6m - CCE 7.16m)
Interest Coverage Ratio = 15.55 (Ebit TTM 12.9m / Interest Expense TTM 829.0k)
FCF Yield = -2.66% (FCF TTM -2.93m / Enterprise Value 110.1m)
FCF Margin = -4.40% (FCF TTM -2.93m / Revenue TTM 66.6m)
Net Margin = 13.48% (Net Income TTM 8.98m / Revenue TTM 66.6m)
Gross Margin = 29.30% ((Revenue TTM 66.6m - Cost of Revenue TTM 47.1m) / Revenue TTM)
Gross Margin QoQ = 19.95% (prev 33.30%)
Tobins Q-Ratio = 1.80 (Enterprise Value 110.1m / Total Assets 61.2m)
Interest Expense / Debt = 1.37% (Interest Expense 227.0k / Debt 16.6m)
Taxrate = 25.20% (403.0k / 1.60m)
NOPAT = 9.64m (EBIT 12.9m * (1 - 25.20%))
Current Ratio = 3.23 (Total Current Assets 47.3m / Total Current Liabilities 14.6m)
Debt / Equity = 0.45 (Debt 16.6m / totalStockholderEquity, last quarter 36.6m)
Debt / EBITDA = 1.11 (Net Debt 15.7m / EBITDA 14.1m)
Debt / FCF = -5.35 (negative FCF - burning cash) (Net Debt 15.7m / FCF TTM -2.93m)
Total Stockholder Equity = 33.7m (last 4 quarters mean from totalStockholderEquity)
RoA = 14.67% (Net Income 8.98m / Total Assets 61.2m)
RoE = 26.67% (Net Income TTM 8.98m / Total Stockholder Equity 33.7m)
RoCE = 30.04% (EBIT 12.9m / Capital Employed (Equity 33.7m + L.T.Debt 9.25m))
RoIC = 19.46% (NOPAT 9.64m / Invested Capital 49.5m)
WACC = 4.97% (E(100.7m)/V(117.3m) * Re(5.62%) + D(16.6m)/V(117.3m) * Rd(1.37%) * (1-Tc(0.25)))
Discount Rate = 5.62% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 8.05%
Shares Correlation 3-Years: -33.33 | Cagr: -3.69%
Fair Price DCF = unknown (Cash Flow -2.93m)
EPS Correlation: 25.57 | EPS CAGR: -24.49% | SUE: -1.54 | # QB: 0
Revenue Correlation: 93.00 | Revenue CAGR: 18.04% | SUE: -0.23 | # QB: 0
Additional Sources for PDEX Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle